Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

Measuring inconsistency in meta-analyses

2003 • 53,662 citations

Meta-analysis in clinical trials

1986 • 36,193 citations

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

2011 • 27,350 citations

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2014 • 26,824 citations

The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants

2017 • 23,395 citations

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

2008 • 16,541 citations

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

2013 • 5,819 citations

Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

2013 • 5,537 citations

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

2013 • 5,320 citations

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1998 • 4,679 citations

Cancer incidence, mortality and prevalence worldwide

2004 • 3,893 citations

The causal relation between human papillomavirus and cervical cancer

2002 • 3,451 citations

The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>

2002 • 3,068 citations

A review of human carcinogens—Part B: biological agents

2009 • 2,713 citations

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions

2007 • 2,003 citations

NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN

1998 • 1,885 citations

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

2007 • 1,820 citations

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

2006 • 1,766 citations

Explaining heterogeneity in meta-analysis: a comparison of methods

1999 • 1,666 citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

2004 • 1,624 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

2002 • 1,570 citations

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

2007 • 1,558 citations

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

2005 • 1,551 citations

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

2013 • 1,523 citations

Global Burden of Human Papillomavirus and Related Diseases

2012 • 1,514 citations

NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA

1967 • 1,370 citations

EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary

2009 • 1,294 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

2015 • 1,192 citations

The Pap Test and Bethesda 2014

2015 • 1,122 citations

Against which human papillomavirus types shall we vaccinate and screen? the international perspective

2004 • 1,099 citations

Worldwide burden of cervical cancer in 2008

2011 • 1,083 citations

Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students

2003 • 1,048 citations

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

2011 • 1,043 citations

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

2008 • 1,039 citations

EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary

2003 • 1,022 citations

HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia

2011 • 877 citations

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

2011 • 822 citations

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

2008 • 817 citations

Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer

2012 • 813 citations

Addressing the vaccine confidence gap

2011 • 806 citations

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

2006 • 803 citations

IARC Handbooks of Cancer Prevention

2003 • 751 citations

The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology

2002 • 750 citations

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

2012 • 692 citations

The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based Study

2000 • 691 citations

Carcinogenicity of human papillomaviruses

2005 • 678 citations

Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention

2006 • 656 citations

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 654 citations

Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection

2007 • 652 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

2009 • 626 citations

Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine

2001 • 605 citations

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

1995 • 597 citations

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

2007 • 581 citations

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

2015 • 579 citations

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

2007 • 566 citations

The carcinogenicity of human papillomavirus types reflects viral evolution

2005 • 552 citations

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

2010 • 547 citations

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

2006 • 527 citations

Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010

2013 • 510 citations

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

2018 • 487 citations

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

2006 • 480 citations

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

2011 • 472 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

2009 • 468 citations

Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine

2009 • 461 citations

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

2006 • 453 citations

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

2006 • 452 citations

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

2009 • 438 citations

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

2013 • 438 citations

Cervical Intra-Epithelial Neoplasia

2009 • 425 citations

Prevention of cervical cancer through papillomavirus vaccination

2004 • 401 citations

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

2010 • 397 citations

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

2012 • 389 citations

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women

2013 • 389 citations

Comparison of the immunogenicity and safety ofCervarix™ andGardasil^®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

2009 • 386 citations

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

2017 • 379 citations

Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries

2005 • 374 citations

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

2010 • 371 citations

Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of Screening

2005 • 359 citations

Surgery for cervical intraepithelial neoplasia

2013 • 358 citations

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

2009 • 347 citations

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

2011 • 329 citations

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

2011 • 314 citations

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

2009 • 312 citations

Trends of cervical cancer mortality in the member states of the European Union

2009 • 304 citations

A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types

2013 • 302 citations

Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents

2007 • 299 citations

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

2014 • 279 citations

Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis

2011 • 276 citations

Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis

2017 • 275 citations

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

2013 • 259 citations

Updated Tests for Small-study Effects in Meta-analyses

2009 • 255 citations

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

2013 • 255 citations

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

2012 • 254 citations

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

2011 • 250 citations

Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease

2017 • 244 citations

Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost

2004 • 242 citations

Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

2007 • 236 citations

Are 20 human papillomavirus types causing cervical cancer?

2014 • 233 citations

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

2009 • 228 citations

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

2014 • 227 citations

Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex Partner

2008 • 225 citations

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

2015 • 221 citations

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

2017 • 217 citations

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

2014 • 215 citations

Efficacy and other milestones for human papillomavirus vaccine introduction

2004 • 214 citations

Chapter 12: Human Papillomavirus Technologies

2003 • 212 citations

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)?

2013 • 208 citations

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

2009 • 205 citations

Meta-analysis regression

1998 • 204 citations

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

2009 • 196 citations

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

2007 • 193 citations

A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult Volunteers

2001 • 193 citations

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

2015 • 188 citations

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

2011 • 188 citations

Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women

2014 • 182 citations

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

2011 • 181 citations

Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection

2007 • 180 citations

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

2014 • 173 citations

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

2016 • 171 citations

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

2014 • 170 citations

Clinical trials of human papillomavirus vaccines and beyond

2013 • 167 citations

European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1

2008 • 165 citations

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

2010 • 164 citations

Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

2011 • 163 citations

The challenges of organising cervical screening programmes in the 15 old member states of the European Union

2009 • 163 citations

Human Papillomavirus Vaccines – Immune Responses

2012 • 163 citations

Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System

2015 • 161 citations

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

2014 • 156 citations

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

2011 • 155 citations

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years

2008 • 154 citations

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

2008 • 152 citations

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

2008 • 149 citations

Chapter 13: Current findings from prophylactic HPV vaccine trials

2006 • 147 citations

Currently approved prophylactic HPV vaccines

2009 • 145 citations

European guidelines for clinical management of abnormal cervical cytology, Part 2

2009 • 140 citations

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study

2013 • 133 citations

Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects

2013 • 130 citations

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

2011 • 124 citations

HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia

2009 • 124 citations

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

2011 • 124 citations

Immunogenicity and Safety of a 9-Valent HPV Vaccine

2015 • 117 citations

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

2008 • 117 citations

Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus‐Like‐Particle Vaccine

2007 • 117 citations

Long-term efficacy and safety of human papillomavirus vaccination

2014 • 114 citations

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety

2015 • 114 citations

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

2013 • 113 citations

Pregnancy and Infant Outcomes in the Clinical Trials of a Human Papillomavirus Type 6/11/16/18 Vaccine

2009 • 113 citations

Papillomavirus vaccines in clinical trials

2003 • 112 citations

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

2009 • 109 citations

Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

2014 • 108 citations

Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women

2013 • 107 citations

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection

2015 • 107 citations

Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old

2011 • 105 citations

Human papillomavirus vaccines

2006 • 104 citations

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

2013 • 96 citations

Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

2007 • 96 citations

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls

2015 • 95 citations

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

2004 • 94 citations

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

2010 • 93 citations

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

2004 • 89 citations

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

2009 • 88 citations

Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme

2014 • 87 citations

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial

2017 • 86 citations

Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women

2010 • 85 citations

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

2010 • 85 citations

Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months

2013 • 84 citations

Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay Titer

2001 • 82 citations

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

2016 • 82 citations

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

2015 • 81 citations

Pregnancy Outcomes From the Pregnancy Registry of a Human Papillomavirus Type6/11/16/18 Vaccine

2009 • 80 citations

Efficacy of Human Papillomavirus Vaccines

2009 • 78 citations

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

2006 • 77 citations

Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in Vietnam

2011 • 75 citations

Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial

2013 • 75 citations

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance

2017 • 75 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women

2007 • 74 citations

Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia

2015 • 73 citations

Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study

2013 • 72 citations

Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women

2013 • 72 citations

Spontaneously Regressing Oral Papillomas Induce Systemic Antibodies That Neutralize Canine Oral Papillomavirus

2000 • 71 citations

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines

2007 • 70 citations

Herpesvirus Infections in Organ Transplant Recipients

2003 • 67 citations

HPV vaccine: Cervarix

2010 • 65 citations

Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK

2013 • 65 citations

Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—The MAM Study

2015 • 62 citations

Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis

2017 • 62 citations

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10–25-Year-Old HIV-Seronegative African Girls and Young Women

2012 • 60 citations

No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England

2017 • 60 citations

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

2011 • 60 citations

Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial

2005 • 60 citations

Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

2014 • 59 citations

Monitoring of human papillomavirus vaccination

2010 • 58 citations

Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel

2010 • 57 citations

Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years

2012 • 57 citations

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

2011 • 57 citations

Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

2010 • 54 citations

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

2016 • 54 citations

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

2013 • 52 citations

Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine

2015 • 52 citations

Systematic review of human papillomavirus vaccine coadministration

2014 • 52 citations

An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine Given Concomitantly With Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccine in Healthy Adolescents 11 to 17 Years of Age

2010 • 51 citations

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

2010 • 50 citations

The Case for Conducting a Randomized Clinical Trial to Assess the Efficacy of a Single Dose of Prophylactic HPV Vaccines Among Adolescents

2015 • 50 citations

Alternative dosage schedules with HPV virus-like particle vaccines

2014 • 48 citations

Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines

2007 • 46 citations

The Efficacy and Duration of Vaccine Protection Against Human Papillomavirus

2014 • 45 citations

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial

2015 • 44 citations

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

2010 • 44 citations

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

2011 • 42 citations

Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs

2013 • 41 citations

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

2012 • 41 citations

Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis

2016 • 41 citations

HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine

2016 • 41 citations

Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (<scp>GARDASIL</scp>) in <scp>J</scp>apanese women aged 18–26 years

2013 • 40 citations

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

2016 • 40 citations

Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study

2016 • 39 citations

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial

2015 • 39 citations

Randomized Trial of an Alternate Human Papillomavirus Vaccine Administration Schedule in College-Aged Women

2010 • 39 citations

Risk of spontaneous abortion and other pregnancy outcomes in 15–25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

2015 • 38 citations

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis–inactivated Poliovirus Vaccine to Girls and Young Women

2010 • 38 citations

Safety and Immunogenicity Profile of Human Papillomavirus-16/18 AS04 Adjuvant Cervical Cancer Vaccine: A Randomized Controlled Trial in Healthy Adolescent Girls of Bangladesh

2011 • 38 citations

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

2011 • 38 citations

Efficacy of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years

2010 • 37 citations

Quadrivalent Human Papillomavirus Vaccine and the Risk of Venous Thromboembolism

2014 • 37 citations

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects

2007 • 37 citations

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

2016 • 37 citations

Immunogenicity of Quadrivalent HPV Vaccine Among Girls 11 to 13 Years of Age Vaccinated Using Alternative Dosing Schedules: Results 29 to 32 Months After Third Dose

2013 • 37 citations

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age

2011 • 36 citations

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

2013 • 36 citations

Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial

2016 • 35 citations

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

2010 • 35 citations

Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes

2015 • 34 citations

Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy

2017 • 33 citations

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

2011 • 33 citations

Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Final Analysis of a Phase 2 Double-Blind, Randomized Controlled Trial

2010 • 33 citations

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

2015 • 32 citations

Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.

2010 • 31 citations

A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18–26 years

2013 • 31 citations

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine in Girls

2011 • 31 citations

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women

2014 • 30 citations

HPV catch-up vaccination of young women: a systematic review and meta-analysis

2014 • 30 citations

Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females

2016 • 29 citations

Guillain–Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States

2013 • 29 citations

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial

2016 • 27 citations

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

2011 • 26 citations

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls

2011 • 26 citations

Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink

2017 • 26 citations

Reported adverse events in girls aged 13–16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands

2011 • 25 citations

Randomized Trial of the Immunogenicity and Safety of the Hepatitis B Vaccine Given in an Accelerated Schedule Coadministered with the Human Papillomavirus Type 16/18 AS04-Adjuvanted Cervical Cancer Vaccine

2011 • 24 citations

Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls

2014 • 24 citations

Surveillance of effects of HPV vaccination in Belgium

2016 • 23 citations

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years

2014 • 23 citations

HPV vaccination coverage among women aged 18–20 years in Germany three years after recommendation of HPV vaccination for adolescent girls

2013 • 23 citations

Safety of the HPV Bivalent and Quadrivalent Vaccines during Pregnancy

2011 • 22 citations

Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials

2014 • 21 citations

Cervical Cytology Biobanking in Europe

2010 • 21 citations

Clinical importance cannot be ruled out using mean difference alone

2015 • 20 citations

Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012

2017 • 20 citations

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

2015 • 19 citations

Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women†

2011 • 19 citations

Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males

2013 • 19 citations

Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011

2015 • 18 citations

Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial

2014 • 18 citations

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

2013 • 17 citations

Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates

2014 • 17 citations

Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy

2015 • 16 citations

Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†

2011 • 11 citations

The Prophylactic Role for the Human Papillomavirus Quadrivalent Vaccine in Males

2010 • 10 citations

Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Cervical Cancer Vaccine in Malaysian Women Aged 18-35 years: A Randomized Controlled Trial.

2014 • 10 citations

Early effects of human papillomavirus vaccination in Belgium

2014 • 10 citations

Preventive Innovation: An Australian Case Study on HPV Vaccination

2013 • 8 citations

Three provinces to study 2-dose HPV vaccine

2007 • 8 citations

Platinum-Resistant and Refractory Ovarian Cancer

2003 • 7 citations

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial

2011 • 7 citations

Cervical Cancer

2003 • 5 citations

Fewer shots proposed to increase uptake of HPV vaccine

2010 • 4 citations

Deleted Work

1955 • 0 citations